Economic impact of tissue testing and treatments of metastatic NSCLC in the era of personalized medicine

Frontiers in Oncology

Volumn 4, Issue SEP, 2014, Pages

  Graham, Donna Marie ^a   Leighl, Natasha B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG ACQUISITION; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; GENOTYPING TECHNIQUE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH SERVICE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL PROCEDURES; MOLECULAR TESTING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY ADJUSTED LIFE YEAR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TISSUE TESTING; TUMOR BIOPSY;

EID: 84907945056     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00258     Document Type: Article

References (48)

1. Mantripragada K, Khurshid H. Targeting genomic alterations in squamous cell lung cancer. Frontiers in oncology. 2013;3:195. PubMed PMID: 23936763. Pubmed Central PMCID: 3733025.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. The New England journal of medicine. 2005 Jul 14;353(2):123-32. PubMed PMID: 16014882.
3. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The lancet oncology. 2012 Oct;13(10):1011-9. PubMed PMID: 22954507. Pubmed Central PMCID: 3936578.
4. Kelly K, Crowley J, Bunn PA, Jr., Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001 Jul 1;19(13):3210-8. PubMed PMID: 11432888.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine. 2002 Jan 10;346(2):92-8. PubMed PMID: 11784875.
6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004 May 1;22(9):1589-97. PubMed PMID: 15117980.
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008 Jul 20;26(21):3543-51. PubMed PMID: 18506025.
8. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004 Jun 1;22(11):2184-91. PubMed PMID: 15169807.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England journal of medicine. 2006 Dec 14;355(24):2542-50. PubMed PMID: 17167137.
10. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. The New England journal of medicine. 2009 Sep 3;361(10):958-67. PubMed PMID: 19692684.
11. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010 Feb 10;28(5):744-52. PubMed PMID: 20038723.
12. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England journal of medicine. 2009 Sep 3;361(10):947-57. PubMed PMID: 19692680.
13. Crystal AS, Shaw AT. New targets in advanced NSCLC: EML4-ALK. Clinical advances in hematology & oncology: H&O. 2011 Mar;9(3):207-14. PubMed PMID: 21475126.
14. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. Journal of the National Cancer Institute. 2011 Jan 19;103(2):117-28. PubMed PMID: 21228314. Pubmed Central PMCID: 3107566.
15. de Oliveira CB, K. E.; Pataky, R.; Gunraj, N.; Haq, M.; Chan, K.; Cheung, W. Y.; Hoch, J. S.; Peacock, S.; Krahn, M. D. Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open. 2013;1(4):E151-E8.
16. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. The American journal of medicine. 2009 Aug;122(8):741-6. PubMed PMID: 19501347.
17. Truven Health Analytics. Red Book online 2014. Available from: http://www.redbook.com/redbook/index.html.
18. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. The Journal of molecular diagnostics: JMD. 2013 Jul;15(4):415-53. PubMed PMID: 23562183.
19. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011 Aug;6(8):1379-91. PubMed PMID: 21709590.
20. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. 2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2014 Apr 8. PubMed PMID: 24718890.
21. Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung cancer. 2012 Apr 76(1):1-18. PubMed PMID: 22138001.
22. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK- rearranged lung adenocarcinomas by standard immunohistochemistry. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010 Mar 1;16(5):1561-71. PubMed PMID: 20179225. Pubmed Central PMCID: 2831135.
23. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non- small cell lung cancer: correlation with fluorescence in situ hybridization. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011 Mar;6(3):466-72. PubMed PMID: 21258247.
24. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011 Mar;6(3):459-65. PubMed PMID: 21278610.
25. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British journal of cancer. 2012 Mar 13;106(6):1100-6. PubMed PMID: 22374459. Pubmed Central PMCID: 3304427.
26. Kamel-Reid S, Chong G, Ionescu DN, Magliocco AM, Spatz A, Tsao M, et al. EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Current oncology. 2012 Apr 19(2):e67-74. PubMed PMID: 22514499. Pubmed Central PMCID: 3320234.
27. Beasley MB, Milton DT. ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice. Journal of oncology practice / American Society of Clinical Oncology. 2011 May;7(3):202-4. PubMed PMID: 21886505. Pubmed Central PMCID: 3092665.
28. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine. 2010 Oct 28;363(18):1693-703. PubMed PMID: 20979469. Pubmed Central PMCID: 3014291.
29. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001 Oct;7(10):2958-70. PubMed PMID: 11595683.
30. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small- cell lung cancer in Asia (IPASS). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011 Jul 20;29(21):2866-74. PubMed PMID: 21670455.
31. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The lancet oncology. 2010 Feb;11(2):121-8. PubMed PMID: 20022809.
32. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine. 2010 Jun 24;362(25):2380-8. PubMed PMID: 20573926.
33. Drummond MFS, M. J. Torrance, G. W. O'Brien, B. J. Stoddart, G. L. Methods for the Economic Evaluation of Health Care Programmes. Third Edition ed. New York.: Oxford University Press; 2005.
34. Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, et al. Guidelines for health technologies: specific guidance for oncology products in Canada. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2012 May;15(3):580-5. PubMed PMID: 22583470.
35. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. Journal of the National Cancer Institute. 2010 Mar 3;102(5):298-306. PubMed PMID: 20160168.
36. Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health technology assessment. 2010 Oct;14(Suppl. 2):71-9. PubMed PMID: 21047494.
37. de Lima Lopes G, Jr., Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost- effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer. 2012 Feb 15;118(4):1032-9. PubMed PMID: 21792863.
38. Handorf EA, McElligott S, Vachani A, Langer CJ Bristol Demeter M, Armstrong K, et al., Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. Journal of oncology practice / American Society of Clinical Oncology. 2012 Sep;8(5):267-74. PubMed PMID: 23277762. Pubmed Central PMCID: 3439225.
39. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The lancet oncology. 2011 Aug;12(8):735-42. PubMed PMID: 21783417.
40. Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ. Targeted erlotinib for first- line treatment of advanced non-small cell lung cancer: a budget impact analysis. Journal of medical economics. 2014 May 12:1-9. PubMed PMID: 24716717.
41. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27):3327-34. PubMed PMID: 23816960.
42. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non- small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The lancet oncology. 2014 Feb;15(2):213-22. PubMed PMID: 24439929.
43. National Institute for Health and Care Excellence (NICE). Afatinib for treating epidermal growth factor receptor mutationpositive locally advanced or metastatic non-small-cell lung cancer. NICE, 2014 April 2014. Report No.
44. Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, et al. Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014 Apr 1;32(10):1012-9. PubMed PMID: 24567430.
45. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non- small cell lung cancer. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2011 Sep-Oct;14(6):836-45. PubMed PMID: 21914503.
46. Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non- small cell lung cancer. Health technology assessment. 2010 May;14 Suppl 1:47-53. PubMed PMID: 20507803.
47. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2011 Dec;22(12):2616-24. PubMed PMID: 22071650. Pubmed Central PMCID: 3493130.
48. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, et al. Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Frontiers in genetics. 2014;5:55. PubMed PMID: 24723936. Pubmed Central PMCID: 3971199.